trial

A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

NCTId NCT04940039
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 93 (actual)
Sponsored by Janssen-Cilag Farmaceutica Ltda.
Primary completion 2024-04-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
93 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2021-07-22
Primary completion
2024-04-16
Eligibility
ALL · 19 Years · 34 Years

Interventions & indications

Drugs
RisperidonePaliperidone

Sponsors

Janssen-Cilag Farmaceutica Ltda.Lead Sponsor

Sites

5 total
Butare, RwandaKibuye, RwandaKigali, RwandaKigali, RwandaRwamagana, Rwanda

Facts & assertions

4 sourced
Enrollment
93
Phase
PHASE4
Primary Completion Date
2024-04-16
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
Paliperidone
drug
lead_sponsor
Janssen-Cilag Farmaceutica Ltda.
company
indication
Schizophrenia
indication
Schizophrenia
indication